1. Clinically significant ocular diseases

2. Pseudoexfoliation or pigment dispersion component glaucoma, history of narrow angle closure glaucoma or narrow angles

3. Previous glaucoma intraocular surgery

4. Refractive surgery in either eye

5. Ocular trauma

6. Ocular infection or inflammation

7. Known hypersensitivity to benzalkonium chloride or excipient of netarsudil ophthalmic solution

8. Cannot demonstrate proper delivery of the eye drop

9. Clinically significant abnormalities in screen lab tests

10. Clinically significant systemic disease

11. Participation in any investigational study within 30 days of screening

12. Women of child-bearing potential who are pregnant, nursing, planning a pregnancy or not using a medically acceptable form of birth control

Efficacy and Systemic Safety of Netarsudil 0.01%, 0.02%, 0.04% Relative to Placebo in Subjects With Open-angle Glaucoma or Ocular Hypertension in Japan